IDH1 Mutations in Prostate Cancer Link High Stage/Grade to Favorable Outcomes
A retrospective analysis identifies IDH1 mutations as a marker for improved survival in prostate cancer, despite aggressive initial presentation.
Prostate SBRT Maintains 90% Relapse-Free Survival at Ten Years
A multi-center trial of 310 patients shows low- and intermediate-risk prostate cancer control remains durable with minimal late toxicity.
Robotic Kidney Transplant Reduces Complication Rates in Randomized Trial
A Danish study finds robot-assisted surgery lowers major and vascular complications by approximately 10 percent compared to open surgery.
Maintenance Pembrolizumab and Radiotherapy Improve Outcomes in Oligometastatic Renal Cell Carcinoma
A pooled analysis of phase 2 trials shows a hazard ratio of 0.57 for progression-free survival when adding immunotherapy to local therapy.
Recurrent Renal Cell Carcinoma Downregulates MHC-I After Adjuvant Atezolizumab
Molecular analysis of IMmotion010 samples suggests a shift toward VEGF-targeted therapy when tumors recur after checkpoint inhibition.
![[89Zr]girentuximab PET Identifies Any Renal Malignancy with 98% Positive Predictive Value](/images/89zrgirentuximab-pet-identifies-any-renal-malignan-April-01-2026.jpg)
[89Zr]girentuximab PET Identifies Any Renal Malignancy with 98% Positive Predictive Value
A secondary analysis of the ZIRCON trial indicates the CAIX-targeted tracer detects non-clear cell subtypes with high clinical accuracy.
Tranexamic Acid Reduces Major Bleeding in Urologic Surgery
A randomized trial of 1,124 patients shows TXA reduces major bleeding by 3.4% without significantly increasing 30-day thrombotic risk.